Prelude Therapeutics Inc 8-K

What Happened

• Prelude Therapeutics Inc. filed a Current Report on Form 8-K on February 3, 2026 and issued a press release announcing that the U.S. Food and Drug Administration cleared the company to proceed with a Phase 1 study under its Investigational New Drug (IND) application for PRT12396.
• PRT12396 is described as a mutant-selective JAK2V617F inhibitor being developed for the treatment of certain myeloproliferative neoplasms. The 8-K notes the disclosure is being furnished (not “filed”) under SEC rules.

Key Details

• Filing date: February 3, 2026 (Form 8-K, Exhibit 99.1 press release).
• Drug: PRT12396 — a mutant-selective JAK2V617F inhibitor.
• Regulatory milestone: FDA cleared Prelude to proceed with a Phase 1 clinical study under its IND.
• Corporate signatory on the filing: Bryant Lim, Chief Financial Officer and Chief Legal Officer.

Why It Matters

• FDA clearance to start a Phase 1 study is a concrete clinical-development milestone: it permits Prelude to begin human testing of PRT12396, advancing the program from preclinical/regulatory preparation into clinical-stage development.
• For investors, this development can be a material company progress indicator — potentially affecting timelines, reporting milestones, and future disclosures about trial start dates, design, and results. The 8-K itself is informational and was furnished with an attached press release; it does not provide trial start dates or clinical data.